Marinus Pharmaceuticals Inc logo

Marinus Pharmaceuticals Inc

$ 5.78 -0.02 (-0.34%) 11:18 AM EST
P/E:
At Loss
P/B:
5.93
Market Cap:
$ 213.93M
Enterprise V:
$ 164.99M
Volume:
40.84K
Avg Vol (2M):
334.46K
Also Trade In:
Volume:
40.84K
Market Cap $:
213.93M
PE Ratio:
At Loss
Avg Vol (2-Month):
334.46K
Enterprise Value $:
164.99M
PB Ratio:
5.93
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Marinus Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Description
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Name Current Vs Industry Vs History
Cash-To-Debt 1.75
Equity-to-Asset 0.29
Debt-to-Equity 1.79
Debt-to-EBITDA -0.84
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.84
Distress
Grey
Safe
Beneish M-Score 1.17
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 59
9-Day RSI 56.37
14-Day RSI 54.98
6-1 Month Momentum % -54.05
12-1 Month Momentum % -57.7

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.91
Quick Ratio 6.91
Cash Ratio 6.47
Days Sales Outstanding 38.03
Days Payable 467.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -41

Financials (Next Earnings Date:2022-11-09 Est.)

MRNS's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:MRNS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 27.725
EPS (TTM) ($) -2.47
Beta 0.69
Volatility % 55.16
14-Day RSI 54.98
14-Day ATR ($) 0.389227
20-Day SMA ($) 5.68525
12-1 Month Momentum % -57.7
52-Week Range ($) 3.97 - 13.15
Shares Outstanding (Mil) 37.14

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Marinus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More